PODD has been the topic of several other research reports. Jefferies Group LLC reiterated a buy rating and issued a $53.00 price objective on shares of Insulet Corporation in a research note on Thursday, April 13th. Zacks Investment Research upgraded Insulet Corporation from a hold rating to a buy rating and set a $57.00 price objective on the stock in a research note on Tuesday, July 18th. Piper Jaffray Companies reiterated an overweight rating and issued a $47.00 price objective on shares of Insulet Corporation in a research note on Monday, May 22nd. B. Riley reiterated a neutral rating and issued a $44.00 price objective on shares of Insulet Corporation in a research note on Sunday, May 14th. Finally, BTIG Research downgraded Insulet Corporation from a buy rating to a neutral rating in a research note on Monday, July 17th. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $50.46.
Shares of Insulet Corporation (NASDAQ:PODD) traded up 0.44% during midday trading on Friday, reaching $54.82. The company’s stock had a trading volume of 278,163 shares. The stock has a 50-day moving average of $51.93 and a 200 day moving average of $45.61. The company’s market cap is $3.18 billion. Insulet Corporation has a 12 month low of $30.69 and a 12 month high of $55.92.
Insulet Corporation (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. The business had revenue of $110 million for the quarter, compared to the consensus estimate of $106.23 million. During the same quarter in the prior year, the business earned ($0.08) earnings per share. Insulet Corporation’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, analysts predict that Insulet Corporation will post ($0.50) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of Insulet Corporation by 7,285.2% in the first quarter. BlackRock Inc. now owns 4,194,117 shares of the medical instruments supplier’s stock valued at $180,724,000 after buying an additional 4,137,326 shares during the period. Norges Bank bought a new position in shares of Insulet Corporation during the fourth quarter valued at about $37,163,000. Clearbridge Investments LLC raised its position in shares of Insulet Corporation by 64.2% in the first quarter. Clearbridge Investments LLC now owns 2,379,224 shares of the medical instruments supplier’s stock valued at $102,521,000 after buying an additional 930,062 shares during the period. Janus Henderson Group PLC acquired a new stake in Insulet Corporation during the second quarter valued at about $27,428,000. Finally, Champlain Investment Partners LLC raised its stake in Insulet Corporation by 19.6% in the first quarter. Champlain Investment Partners LLC now owns 1,144,875 shares of the medical instruments supplier’s stock valued at $49,333,000 after buying an additional 187,630 shares during the last quarter.
About Insulet Corporation
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with MarketBeat.com's FREE daily email newsletter.